Shots:

• The study involved 1402 patients across 3 cohorts: a) 81 patients in Arizona (34 with AD and 47 without)- b) 699 in Sweden (301 with no cognitive impairment- 178 with mild cognitive impairment- 121 with AD dementia and 99 with other neurodegenerative diseases) and c) 622 in Colombia (365 with E280A mutations and 257 noncarriers)
• Results:  P-tau217 accurately identified AD from other neurodegenerative diseases in both 1&2 cohort while in 3rd cohort P-tau217 was elevated in mutation carriers' blood for 20yrs.before anticipated symptom onset and was associated with memory performance- published in JAMA
• P-tau217 is better than blood-based biomarkers or MRI but did not perform significantly better than cerebrospinal fluid- or PET-based tau biomarkers. Moreover- the test has the potential together with digital tools for checking memory performance like smartphone apps- to improve the diagnosis of AD

 Ref: Eli Lilly | Image: Eli Lilly